The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:DiVA.org:uu-204855" > The Long-Term Multi...

1 av 1
Föregående post
Nästa post
Till träfflistan

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		05010naa a2200925 4500
001		oai:DiVA.org:uu-204855
003		SwePub
008		130812s2013 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2048552 URI
024	7	a https://doi.org/10.1161/CIRCULATIONAHA.112.0011392 DOI
040		a (SwePub)uu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Connolly, Stuart J.4 aut
245	1 0	a The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
264	1	c 2013
338		a print2 rdacarrier
500		a Clinical Trial Registration URL: Unique identifier: NCT00808067.
520		a Background During follow-up of between 1 and 3 years in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were shown to be effective and safe for the prevention of stroke or systemic embolism in patients with atrial fibrillation. There is a need for longer-term follow-up of patients on dabigatran and for further data comparing the 2 dabigatran doses. Methods and Results Patients randomly assigned to dabigatran in RE-LY were eligible for the Long-term Multicenter Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) trial if they had not permanently discontinued study medication at the time of their final RE-LY study visit. Enrolled patients continued to receive the double-blind dabigatran dose received in RE-LY, for up to 28 months of follow up after RE-LY (median follow-up, 2.3 years). There were 5851 patients enrolled, representing 48% of patients originally randomly assigned to receive dabigatran in RE-LY and 86% of RELY-ABLE-eligible patients. Rates of stroke or systemic embolism were 1.46% and 1.60%/y on dabigatran 150 and 110 mg twice daily, respectively (hazard ratio, 0.91; 95% confidence interval, 0.69-1.20). Rates of major hemorrhage were 3.74% and 2.99%/y on dabigatran 150 and 110 mg (hazard ratio, 1.26; 95% confidence interval, 1.04-1.53). Rates of death were 3.02% and 3.10%/y (hazard ratio, 0.97; 95% confidence interval, 0.80-1.19). Rates of hemorrhagic stroke were 0.13% and 0.14%/y. Conclusions During 2.3 years of continued treatment with dabigatran after RE-LY, there was a higher rate of major bleeding with dabigatran 150 mg twice daily in comparison with 110 mg, and similar rates of stroke and death.
653		a atrial fibrillation
653		a dabigatran
653		a hemorrhage
653		a stroke
700	1	a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)larswall
700	1	a Ezekowitz, Michael D.4 aut
700	1	a Eikelboom, John4 aut
700	1	a Oldgren, Jonasu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi4 aut0 (Swepub:uu)jonaoldg
700	1	a Reilly, Paul A.4 aut
700	1	a Brueckmann, Martina4 aut
700	1	a Pogue, Janice4 aut
700	1	a Alings, Marco4 aut
700	1	a Amerena, John V.4 aut
700	1	a Avezum, Alvaro4 aut
700	1	a Baumgartner, Iris4 aut
700	1	a Budaj, Andrzej J.4 aut
700	1	a Chen, Jyh-Hong4 aut
700	1	a Dans, Antonio L.4 aut
700	1	a Darius, Harald4 aut
700	1	a Di Pasquale, Giuseppe4 aut
700	1	a Ferreira, Jorge4 aut
700	1	a Flaker, Greg C.4 aut
700	1	a Flather, Marcus D.4 aut
700	1	a Franzosi, Maria Grazia4 aut
700	1	a Golitsyn, Sergey P.4 aut
700	1	a Halon, David A.4 aut
700	1	a Heidbuchel, Hein4 aut
700	1	a Hohnloser, Stefan H.4 aut
700	1	a Huber, Kurt4 aut
700	1	a Jansky, Petr4 aut
700	1	a Kamensky, Gabriel4 aut
700	1	a Keltai, Matyas4 aut
700	1	a Kim, Sung Soon4 aut
700	1	a Lau, Chu-Pak4 aut
700	1	a Le Heuzey, Jean-Yves4 aut
700	1	a Lewis, Basil S.4 aut
700	1	a Liu, Lisheng4 aut
700	1	a Nanas, John4 aut
700	1	a Omar, Razali4 aut
700	1	a Pais, Prem4 aut
700	1	a Pedersen, Knud E.4 aut
700	1	a Piegas, Leopoldo S.4 aut
700	1	a Raev, Dimitar4 aut
700	1	a Smith, Pal J.4 aut
700	1	a Talajic, Mario4 aut
700	1	a Tan, Ru San4 aut
700	1	a Tanomsup, Supachai4 aut
700	1	a Toivonen, Lauri4 aut
700	1	a Vinereanu, Dragos4 aut
700	1	a Xavier, Denis4 aut
700	1	a Zhu, Jun4 aut
700	1	a Wang, Susan Q.4 aut
700	1	a Duffy, Christine O.4 aut
700	1	a Themeles, Ellison4 aut
700	1	a Yusuf, Salim4 aut
710	2	a Uppsala universitetb Uppsala kliniska forskningscentrum (UCR)4 org
773	0	t Circulationg 128:3, s. 237-243q 128:3<237-243x 0009-7322x 1524-4539
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-204855
856	4 8	u https://doi.org/10.1161/CIRCULATIONAHA.112.001139

Hitta via bibliotek

Circulation (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Connolly, Stuart ...; Wallentin, Lars; Ezekowitz, Micha ...; Eikelboom, John; Oldgren, Jonas; Reilly, Paul A.; visa fler...; Brueckmann, Mart ...; Pogue, Janice; Alings, Marco; Amerena, John V.; Avezum, Alvaro; Baumgartner, Iri ...; Budaj, Andrzej J ...; Chen, Jyh-Hong; Dans, Antonio L.; Darius, Harald; Di Pasquale, Giu ...; Ferreira, Jorge; Flaker, Greg C.; Flather, Marcus ...; Franzosi, Maria ...; Golitsyn, Sergey ...; Halon, David A.; Heidbuchel, Hein; Hohnloser, Stefa ...; Huber, Kurt; Jansky, Petr; Kamensky, Gabrie ...; Keltai, Matyas; Kim, Sung Soon; Lau, Chu-Pak; Le Heuzey, Jean- ...; Lewis, Basil S.; Liu, Lisheng; Nanas, John; Omar, Razali; Pais, Prem; Pedersen, Knud E ...; Piegas, Leopoldo ...; Raev, Dimitar; Smith, Pal J.; Talajic, Mario; Tan, Ru San; Tanomsup, Supach ...; Toivonen, Lauri; Vinereanu, Drago ...; Xavier, Denis; Zhu, Jun; Wang, Susan Q.; Duffy, Christine ...; Themeles, Elliso ...; Yusuf, Salim; visa färre...

Artiklar i publikationen: Circulation

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se